Ziegler M G, Wilner K D
University of California Medical Center, San Diego, USA.
J Clin Psychiatry. 1996;57 Suppl 1:12-5.
A double-blind, placebo-controlled, randomized, crossover study was conducted to determine the effect of sertraline on the beta-adrenergic blocking activity of atenolol in 10 healthy male volunteers.
To assess the existence of any possible pharmacodynamic interaction between sertraline and atenolol, the effect of sertraline and placebo on the dose of intravenous isoproterenol required to increase heart rate by 25 beats per minute (bpm; chronotropic dose25 [CD25]) and the change in heart rate during exercise in atenolol-treated subjects were determined.
The mean CD25 of isoproterenol was 2.00 micrograms after administration of placebo plus atenolol 50 mg and 2.03 micrograms after administration of sertralnie 100 micrograms plus atenolol 50 mg. The mean heart rate during exercise testing decreased by 29 bpm after sertraline plus atenolol administration and by 31 bpm after placebo plus atenolol administration. Analysis of variance indicated no statistically significant treatment or sequence effects. Only 1 subject experienced an adverse event--a mild headache after administration of sertraline plus atenolol. No clinically significant electrocardiograph changes were observed after sertraline or placebo administration.
The results of this study demonstrate that sertraline does not alter the beta-blocking activity of atenolol.
进行了一项双盲、安慰剂对照、随机交叉研究，以确定舍曲林对10名健康男性志愿者中阿替洛尔β肾上腺素能阻滞活性的影响。
为评估舍曲林与阿替洛尔之间是否存在任何可能的药效学相互作用，测定了舍曲林和安慰剂对使心率每分钟增加25次（bpm；变时剂量25 [CD25]）所需的静脉注射异丙肾上腺素剂量的影响，以及阿替洛尔治疗受试者运动期间心率的变化。
服用安慰剂加50 mg阿替洛尔后，异丙肾上腺素的平均CD25为2.00微克；服用100微克舍曲林加50 mg阿替洛尔后，平均CD25为2.03微克。舍曲林加阿替洛尔给药后运动测试期间的平均心率下降了29 bpm，安慰剂加阿替洛尔给药后下降了31 bpm。方差分析表明，治疗或顺序效应无统计学显著差异。只有1名受试者出现不良事件——服用舍曲林加阿替洛尔后出现轻度头痛。服用舍曲林或安慰剂后未观察到具有临床意义的心电图变化。
本研究结果表明，舍曲林不会改变阿替洛尔的β受体阻滞活性。
